Search
  • EPA-Insight

OSE Immunotherapeutics Receives New European Patent Protection

OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients




OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) today announces the grant of a new patent from the European Patent Office (EPO) strengthening the protection covering OSE-703, a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7 (CD127) making it cytotoxic for human cells expressing CD127, and its use thereof in immuno-oncology treatment.

The new patent covers OSE-703 until at least 2037. This is the first patent granted in Europe for OSE-703 and represents a major step in strengthening the product’s protection. Additionally, this patent should facilitate the granting of additional patents in other major territories covered by the same patent family.

“We are very pleased with this first European patent that simultaneously reinforces OSE-703 intellectual property and its position in our portfolio as an IL-7R directed immunotherapy for cancer treatment,” commented Alexis Peyroles, chief executive officer of OSE Immunotherapeutics.


OSE-703 is being explored preclinically in collaboration with Memorial Sloan Kettering Cancer Center to define its efficacy profile and potential development strategy for solid tumors with non-small cell lung cancer (NSCLC) and mesothelioma as primary models. The research program is conducted by physician-scientist Prasad S. Adusumilli, M.D., FACS, an expert in tumor immunology with a focus on the development of chimeric antigen receptor T-cell (CAR T-cell) immunotherapy.


Source - https://ose-immuno.com/en/press-releases/

24 views

© 2019 by EPA-Insight

Follow Us

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon
  • Grey YouTube Icon